Copyright
©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 14, 2012; 18(10): 1104-1109
Published online Mar 14, 2012. doi: 10.3748/wjg.v18.i10.1104
Published online Mar 14, 2012. doi: 10.3748/wjg.v18.i10.1104
Table 2 Response to treatment n (%)
| Response | Patients | CR | PR | SD | PD | Unknown |
| Overall | 40 | 0 (0.0) | 3 (7.5) | 21 (52.5) | 15 (37.5) | 1 (2.5) |
| 2nd line | 17 | 0 (0.0) | 2 (13.3) | 11 (64.7) | 4 (23.5) | 0 (0.0) |
| 3rd line | 13 | 0 (0.0) | 1 (7.7) | 6 (46.2) | 5 (38.5) | 1 (7.7) |
| 4th or later-line | 10 | 0 (0.0) | 0 (0.0) | 4 (40.0) | 6 (60.0) | 0 (0.0) |
- Citation: Park LC, Lee HS, Shin SH, Park SJ, Park MI, Oh SY, Kwon HC, Baek JH, Choi YJ, Kang MJ, Kim YS. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer. World J Gastroenterol 2012; 18(10): 1104-1109
- URL: https://www.wjgnet.com/1007-9327/full/v18/i10/1104.htm
- DOI: https://dx.doi.org/10.3748/wjg.v18.i10.1104